Datos a fecha 01/05/26 14:04
| Ticker | FHTX |
|---|---|
| ISIN | US3441741077 |
| Sector | Atención sanitaria |
| Industria | Biotechnology |
| Mercado | NASDAQ |
| Capitalización | 278.825.950 € |
| Beta | 3,11 |
| Sitio web | https://foghorntx.com |
| CEO | Adrian H. Gottschalk |
| Fecha de IPO | 23/10/2020 |
| País | US |
| Dirección | 500 Technology Square, Cambridge, MA, 02139 |
| Volumen | 106.234 |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory ...
El precio actual de Foghorn Therapeutics Inc. (FHTX) es de 4,75 , con una variación del -0,21%.
Foghorn Therapeutics Inc. opera en el sector Healthcare, industria Biotechnology.
Compara brokers con acceso a las principales bolsas internacionales, con bajas comisiones, custodia y herramientas de análisis para invertir en acciones.
Compara brokers para acciones